You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 44 No. 12, December 1987 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Monoamine Neurotransmitter Interactions and the Prediction of Antidepressant Response

John K. Hsiao, MD; Hans Agren, MD; John J. Bartko, PhD; Matthew V. Rudorfer, MD; Markku Linnoila, MD, PhD; William Z. Potter, MD, PhD

Arch Gen Psychiatry. 1987;44(12):1078-1083.


Abstract

• Clinical studies of monoamine neurotransmitter function in depression have concentrated on individual monoamines without focusing on interactions between monoamine systems. Virtually all modern studies have found significant correlations between monoamine metabolite concentrations in cerebrospinal fluid (CSF). These correlations should in part reflect interactions between central monoamine systems. In the present analysis, CSF had been obtained from depressed patients before (n = 40) and after (n =36) antidepressant treatment. The patients were grouped based on their response to treatment. Absolute concentrations of CSF monoamine metabolites (homovanillic acid, 5-hydroxyindoleacetic acid, and 3-methoxy-4-hydroxyphenylethyleneglycol) did not differ between the two groups before or after treatment. However, when correlations between metabolites were compared, nonresponders to treatment differed considerably from responders. In responders, as in previously described normal populations, all three metabolites correlated with one another before and after treatment, and treatment-induced changes in metabolite concentrations also correlated with one another. In contrast, metabolites in nonresponders did not correlate with one another before treatment, nor did treatment-induced changes correlate with one another in this group. Furthermore, correlations between treatment-induced changes in metabolites differed significantly between responders and nonresponders, and there was a trend for pretreatment correlations to differ as well. The lack of correlation between monoamine metabolites in nonresponders suggests that interactions between monoamine systems may be disrupted in these individuals. Using CSF metabolite correlations to study neurotransmitter interactions may have clinical relevance and yields information not available from examining neurotransmitters in isolation.



Author Affiliations

From the Section on Clinical Pharmacology, Laboratory of Clinical Sciences (Drs Hsiao, Agren, Rudorfer, and Potter), and the Division of Biometry and Applied Sciences (Dr Bartko), National Institute of Mental Health, Bethesda, Md; the Department of Psychiatry, University Hospital, Uppsala, Sweden (Dr Agren); and the Laboratory of Clinical Studies, National Institute on Alcohol Abuse and Alcoholism, Division of Intramural Clinical and Biological Research, Bethesda, Md (Dr Linnoila).


Footnotes

Accepted for publication Aug 4, 1987.

Reprint requests to Section on Clinical Pharmacology, Laboratory of Clinical Science, NIMH, Bldg 10, Room 2D46, Bethesda, MD 20892 (Dr Hsiao).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Differential Brain Metabolic Predictors of Response to Paroxetine in Obsessive-Compulsive Disorder Versus Major Depression
Saxena et al.
Am. J. Psychiatry 2003;160:522-532.
ABSTRACT | FULL TEXT  

Signal Transduction Pathways: Molecular Targets for Lithium's Actions
Manji et al.
Arch Gen Psychiatry 1995;52:531-543.
ABSTRACT  

Changes in Cerebrospinal Fluid Neurochemistry During Treatment of Obsessive-compulsive Disorder With Clomipramine
Altemus et al.
Arch Gen Psychiatry 1994;51:794-803.
ABSTRACT  

Effect of Neuroleptic Medication on Cerebrospinal Fluid Monoamine Metabolite Concentrations in Schizophrenia: Serotonin-Dopamine Interactions as a Target for Treatment
Kahn et al.
Arch Gen Psychiatry 1993;50:599-605.
ABSTRACT  

Monoamine Neurotransmitter Interactions in Drug-Free and Neuroleptic-Treated Schizophrenics
John et al.
Arch Gen Psychiatry 1993;50:606-614.
ABSTRACT  

Are Monoamine Metabolites in Cerebrospinal Fluid Worth Measuring?
Arch Gen Psychiatry 1993;50:653-656.
ABSTRACT  

The Mechanisms of Action of Lithium: II. Effects on Adenylate Cyclase Activity and {beta}-Adrenergic Receptor Binding in Normal Subjects
Risby et al.
Arch Gen Psychiatry 1991;48:513-524.
ABSTRACT  

Cerebrospinal Fluid and Plasma Monoamine Metabolites and Their Relation to Psychosis: Implications for Regional Brain Dysfunction in Schizophrenia
Pickar et al.
Arch Gen Psychiatry 1990;47:641-648.
ABSTRACT  

Serotonergic Studies in Patients With Affective and Personality Disorders: Correlates With Suicidal and Impulsive Aggressive Behavior
Coccaro et al.
Arch Gen Psychiatry 1989;46:587-599.
ABSTRACT  

Biochemical Classifications of Diagnostic Subgroups and D-Type Scores
Potter and Linnoila
Arch Gen Psychiatry 1989;46:269-271.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1987 American Medical Association. All Rights Reserved.